Meta facebook tracking pixel

Listen Now

Topics Covered

  • Overview of Waldenstrom’s Macroglobulinemia, including Staging
  • Symptoms & Signs
  • Front Line Treatment for WM
  • Treatment for Relapsed/Refractory WM
  • Current Standard of Care & New Treatment Approaches
  • Translating Genomic Findings into New Treatment Opportunities for WM
  • Clinical Trials: How Research Contributes to Your Treatment Options
  • Controlling Symptoms & Treatment Side Effects, including Reducing Complications
  • Peripheral Neuropathy
  • Follow-Up Care Appointments & Plans
  • Communicating with Your Health Care Team about Your Quality-of-Life
  • Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, Prepared List of Questions & Discussion of OpenNotes
  • Questions for Our Panel of Experts

Our Panel of Experts

Presenter

Andrew Branagan, MD, PhD

Attending Physician, Massachusetts General Hospital Cancer Center, Harvard Medical School

Presenter

Shayna Sarosiek, MD

Physician, Assistant Professor of Medicine, Harvard Medical School, Bing Center for Waldenstrom’s Macroglobulinemia, Dana Farber Cancer Institute

Presenter

Prashant Kapoor, MD, FACP

Associate Professor of Medicine, Consultant, Division of Hematology, Mayo Clinic

Presenter

Peter DeNardis

IWMF Chair of the Board of Trustees, The International Waldenstrom’s Macroglobulinemia Foundation (IWMF)

Presenter

Carolyn Messner, DSW, BCD, FAPOS, FAOSW

Senior Director of Education and Training, CancerCare

Brochure

You can download the brochure for this workshop Download button

Workshop Date

This workshop was originally recorded on 2022-05-25.

Search by:

Diagnosis

Topic

The information presented in this workshop is provided for your general information only. It is not intended as medical advice and should not be relied upon as a substitute for consultations with qualified health professionals who are aware of your specific situation. We encourage you to take information and questions back to your individual health care provider as a way of creating a dialogue and partnership about your cancer and your treatment.

Back to Top

Terms of Use and Privacy Policy

By using our website, you agree to our recently updated Privacy Policy . Here you can read more about our use of cookies which help us make continuous improvements to our website. Privacy Policy.